10-K: Capricor Therapeutics Outlines Share Structure and Regulatory Framework in 10-K Filing

Capricor Therapeutics' 10-K filing details its capital structure, stock information, and regulatory landscape, emphasizing its focus on cell and exosome-based therapies.

Summary

• Capricor Therapeutics, Inc. has an authorized capital stock of 55,000,000 shares, including 50,000,000 common shares and 5,000,000 preferred shares, each with a par value of $0.001.
• The company's common stock is listed on the Nasdaq Capital Market under the symbol CAPR.
• Holders of common stock are entitled to one vote per share and share ratably in dividends and liquidation proceeds after preferred stock holders.
• The board of directors is authorized to issue up to 5,000,000 shares of preferred stock without stockholder action, which could affect the voting power of common stockholders.
• As of December 31, 2023, there were no shares of preferred stock issued and outstanding.
• The company is subject to Section 203 of the Delaware General Corporation Law, which may have anti-takeover effects.
• The bylaws allow special meetings of stockholders to be called by the Chairman, President, or board, or by holders of at least 10% of the voting shares.
• Stockholder proposals require written notice to the Secretary not later than 30 days prior to the meeting.
• Vacancies on the board may be filled only by a majority of the remaining directors.
• The transfer agent and registrar for the common stock is Equiniti Trust Company, LLC.
• As of March 7, 2024, there were 31,399,667 shares of common stock issued and outstanding.
• The aggregate market value of the company's common stock held by non-affiliates as of June 30, 2023, was approximately $119.7 million, based on a price of $4.78 per share.
• The company has raised approximately $145 million in equity capital and $90 million in non-dilutive funding from partners and government sources.
• The company's core therapeutic areas include Duchenne muscular dystrophy (DMD) and SARS-CoV-2.
• The company's pipeline includes CAP-1002 for DMD, an exosome protein-based vaccine for SARS-CoV-2, engineered exosomes for RNA, protein and small molecule delivery, and CDC-derived exosomes (CAP-2003) for DMD.
• The company has two manufacturing facilities for CAP-1002, one in Los Angeles and one in San Diego.
• The company has a Commercialization and Distribution Agreement with Nippon Shinyaku for CAP-1002 in the United States and Japan.
• The company has a collaboration agreement with the NIH for a Phase 1 clinical study of its StealthX vaccine.
• The company has a Cooperative Research and Development Agreement with the U.S. Army Institute of Surgical Research.
• The company has exclusive license agreements with the University of Rome, JHU, and CSMC for intellectual property rights related to cardiac-derived cells and exosomes.
• The company has 46 granted patents and 15 pending patent applications related to its CDC technology and 37 granted patents and 43 pending patent applications related to its exosome technology.
• CAP-1002 has received orphan drug, Regenerative Medicine Advanced Therapy (RMAT), and Rare Pediatric Disease designations from the FDA.
• The company has 102 employees, with 101 full-time employees and 34 holding advanced degrees.

Sentiment

Score: 4

Explanation: The document highlights both positive aspects, such as the company's diverse pipeline and strategic partnerships, and negative aspects, such as the company's lack of profitability and dependence on future funding. The overall sentiment is cautiously optimistic, with significant risks and uncertainties.

Positives

• The company has secured significant funding through equity and non-dilutive sources.
• The company has a diverse pipeline of cell and exosome-based therapies.
• The company has established manufacturing capabilities for its lead product candidate, CAP-1002.
• The company has secured commercialization and distribution agreements with Nippon Shinyaku for CAP-1002 in key markets.
• The company has a collaboration agreement with the NIH for its exosome-based vaccine program.
• The company has a strong intellectual property portfolio with numerous granted patents and pending applications.
• CAP-1002 has received multiple regulatory designations, including orphan drug, RMAT, and rare pediatric disease designations.

Negatives

• The company has no commercial products and has incurred significant losses.
• The company is dependent on third parties for manufacturing and distribution.
• The company is subject to anti-takeover provisions that may deter potential acquirers.
• The company's bylaws may make it difficult for stockholders to effect changes in management.
• The company's future success depends on the outcome of clinical trials and regulatory approvals.
• The company is subject to intense competition in the pharmaceutical and biotechnology industries.
• The company's manufacturing facilities are subject to extensive regulations and may not be approved for commercial production.
• The company is subject to potential product liability claims.

Risks

• The company needs substantial additional funding to complete the development of its product candidates.
• The company has incurred significant losses and may never be profitable.
• The company may not have adequate personnel and may not be able to attract or retain personnel needed to develop its products.
• The company's success depends upon the viability of its product candidates, all of which require regulatory approval to commercialize.
• Delays in commencement, enrollment, and completion of clinical testing could result in increased costs and delay or limit the ability to obtain regulatory approval.
• The company's exosome technologies are unproven in their ability to achieve sufficient biological activity or scale in development to date.
• The company may not be able to use its facilities to manufacture CAP-1002 product for commercial purposes.
• The company may be required to obtain consent from CSMC in order to sell commercial product from its Los Angeles facility.
• The company may not be able to satisfy clinical and/or regulatory requirements necessary for the approval of its product in the U.S. or Japan.
• The company may not be able to reach the milestones set forth in its distribution agreements.
• The company's partners may not perform as expected.
• The manufacturing of the company's product candidates is heavily reliant on supply chain requirements.
• The company may need to rely upon third-party manufacturers for the expansion of its manufacturing capabilities.
• The company may not have adequate manufacturing facilities required for any scale-up of manufacturing.
• The company may not be able to replicate its manufacturing processes.
• The company may not be able to comply with cGMP regulations.
• The company may not be able to identify or retain necessary manufacturing personnel.
• The FDA may not accept the viability or comparability of the company's manufacturing processes.
• The FDA may not approve the company's manufacturing facilities for the manufacture of commercial products.
• The company may not be able to obtain, maintain, protect, and enforce its intellectual property rights.
• The company may face potential challenges to the validity, enforceability, or scope of its intellectual property.
• The company may experience claims from third parties that it is infringing their patents or other intellectual property rights.
• The company may not be able to satisfy its obligations under its licensing agreements.
• The company depends on its relationships with its licensors, collaborators, and other third parties and there is no guarantee that such relationships will continue.
• The company will depend on the ability of Nippon Shinyaku to perform according to the terms of the U.S. Distribution and Japan Distribution Agreements.
• The company's products will likely face intense competition.
• Any of the company's product candidates for which it receives regulatory approval may not achieve broad market acceptance.
• The company's products may expose it to potential product liability.
• The company's stock price will likely continue to fluctuate significantly.
• The company has never paid dividends and does not anticipate paying dividends in the future.

Future Outlook

The company expects to incur significant expenses and operating losses for the foreseeable future and will need to raise substantial additional capital to fund its operations.

Industry Context

The company operates in the highly competitive pharmaceutical and biotechnology industries, facing competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as academic institutions and government agencies.

Comparison to Industry Standards

• The company's approach to DMD treatment with CAP-1002, focusing on immunomodulatory, anti-inflammatory, and anti-fibrotic actions, contrasts with exon-skipping oligonucleotides and gene therapy approaches that aim to restore dystrophin expression, which are being pursued by companies like Sarepta Therapeutics.
• The company's exosome platform is a novel approach, and there are no approved exosome-based therapeutics in the U.S. to date, making it difficult to compare to industry standards.
• The company's manufacturing capabilities are being developed in-house, which is different from some companies that rely solely on contract manufacturers.
• The company's reliance on strategic partnerships for commercialization is a common strategy in the biotechnology industry, but the success of these partnerships is not guaranteed.
• The company's receipt of orphan drug, RMAT, and rare pediatric disease designations is consistent with other companies developing therapies for rare diseases.

Legal Proceedings

• The company recently received a letter from CSMC alleging certain overdue payment obligations and alleged breaches of the Amended CSMC License Agreement.

Related Party Transactions

• The company has lease agreements with Cedars-Sinai Medical Center (CSMC), a related party.
• The company has consulting agreements with Dr. Frank Litvack and Dr. Eduardo Marbn, who are related parties.
• The company has accounts payable and accrued expenses to related parties, including CSMC.

Stakeholder Impact

• Shareholders may experience dilution from future equity offerings.
• Shareholders may lose their entire investment if the company's business plans are not successful.
• Employees may be affected by changes in the company's operations and financial condition.
• Patients may benefit from the development of new therapies for DMD and other diseases.
• The company's partners and collaborators may be affected by the company's financial performance and strategic decisions.

Next Steps

• The company plans to continue the development of its CAP-1002 program for the treatment of DMD.
• The company plans to advance its exosome technology for therapeutic development.
• The company plans to evaluate strategic collaborations to accelerate development and commercialization timelines.
• The company plans to meet with the FDA in the first quarter of 2024 to discuss its pathway to BLA for CAP-1002.
• The company expects to have topline data available from Cohort A of the HOPE-3 trial in the fourth quarter of 2024.
• The company plans to complete enrollment for Cohort B of the HOPE-3 trial in the second quarter of 2024.
• The company expects to have three-year data available from the HOPE-2 OLE study in the second quarter of 2024.
• NIAID plans to initiate a Phase 1 clinical trial with the company's StealthX vaccine in late 2024, subject to regulatory approval.

Key Dates

Keywords

Capricor Therapeutics, Duchenne muscular dystrophy, DMD, CAP-1002, exosomes, cell therapy, biotechnology, clinical trials, manufacturing, intellectual property, Nippon Shinyaku, FDA, RMAT, orphan drug, StealthX vaccine, SARS-CoV-2